Incannex Healthcare Inc. has announced the successful completion of its RePOSA Phase 2 clinical trial database lock for IHL-42X, a drug candidate aimed at treating obstructive sleep apnoea (OSA). This milestone, achieved on June 16, 2025, enables the commencement of final statistical analysis. The top-line results of the trial are expected to be released in July 2025. The trial focuses on patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). IHL-42X is being developed as a fixed-dose combination therapy designed to reduce apnea episodes and improve sleep quality, aiming to provide an alternative to current treatments in a field where no approved oral pharmacological treatments currently exist.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。